Summary
Uromodulin (UMOD) malfunction has been found in a range of autosomal dominant tubulointerstitial nephropathies associated with hyperuricaemia, gouty arthritis, medullary cysts and renal failure—labelled as familial juvenile hyperuricaemic nephropathy, medullary cystic disease type 2 and glomerulocystic kidney disease. To gain knowledge of the spectrum of UMOD changes in various genetic diseases with renal involvement we examined urinary UMOD excretion and found significant quantitative and qualitative changes in 15 male patients at various clinical stages of Fabry disease. In untreated patients, the changes ranged from normal to a marked decrease, or even absence of urinary UMOD. This was accompanied frequently by the presence of aberrantly processed UMOD lacking the C-terminal part following the K432 residue. The abnormal patterns normalized in all patients on enzyme replacement therapy and in some patients on substrate reduction therapy. Immunohistochemical analysis of the affected kidney revealed abnormal UMOD localization in the thick ascending limb of Henle’s loop and the distal convoluted tubule, with UMOD expression inversely proportional to the degree of storage. Our observations warrant evaluation of tubular functions in Fabry disease and suggest UMOD as a potential biochemical marker of therapeutic response of the kidney to therapy. Extended comparative studies of UMOD expression in kidney specimens obtained during individual types of therapies are therefore of great interest.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13(Supplement 2): S134–138.
Bernascone I, Vavassori S, Di Pentima A, et al (2006) Defective intracellular trafficking of uromodulin mutant isoforms. Traffic 7: 1567–1579.
Bleyer AJ, Trachtman H, Sandhu J, Gorry MC, Hart TC (2003) Renal manifestations of a mutation in the uromodulin (Tamm Horsfall protein) gene. Am J Kidney Dis 42: E20–26.
Bleyer AJ, Hart TC, Shihabi Z, Robins V, Hoyer JR (2004) Mutations in the uromodulin gene decrease urinary excretion of Tamm-Horsfall protein. Kidney Int 66: 974–977.
Breunig F, Wanner C (2003) Enzyme replacement therapy for Fabry disease: proving the clinical benefit. Nephrol Dial Transplant 18: 7–9.
Burkholder PM, Updike SJ, Ware RA, Reese OG (1980) Clinicopathologic, enzymatic, and genetic features in a case of Fabry’s disease. Arch Pathol Lab Med 104: 17–25.
Cavallone D, Malagolini N, Serafini-Cessi F (2001) Mechanism of release of urinary Tamm-Horsfall glycoprotein from the kidney GPI-anchored counterpart. Biochem Biophys Res Commun 280: 110–114.
Chakraborty J, Below AA, Solaiman D (2004) Tamm-Horsfall protein in patients with kidney damage and diabetes. Urol Res 32: 79–83.
Christensen EI, Zhou Q, Sorensen SS, et al (2007) Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice. J Am Soc Nephrol 18: 698–706.
Clapp WL, Croker BP (1997) Adult kidney. In: Sternberg SS, ed. Histology for Pathologists, 2nd edn. Philadelphia: Lippincott-Raven, 799–834.
Cohen AH (1981) Morphology of renal tubular hyaline casts. Lab Invest 44: 280–287.
Dahan K, Devuyst O, Smaers M, et al (2003) A cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulin. J Am Soc Nephrol 14: 2883–2893.
De Schoenmakere G, Chauveau D, Grunfeld JP (2003) Enzyme replacement therapy in Anderson-Fabry’s disease: beneficial clinical effect on vital organ function. Nephrol Dial Transplant 18: 33–35.
del Toro N, Milan JA, Palma A (2004) Enzyme replacement in the treatment of Fabry’s disease. Is there a point-of-no-return? Nephrol Dial Transplant 19: 1018.
Dempsey H, Hartley MW, Carroll J, Balint J, Miller RE, Frommeyer WB Jr. (1965) Fabry’s disease (angiokeratoma corporis diffusum): case report on a rare disease. Ann Intern Med 63: 1059–1068.
Desnick RJ, Astrin KH, Bishop DF (1989) Fabry disease: molecular genetics of the inherited nephropathy. Adv Nephrol Necker Hosp 18: 113–127.
Dobrovolny R, Dvorakova L, Ledvinova J, et al (2005) Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med 83: 647–654.
Fairley JK, Owen JE, Birch DF (1983) Protein composition of urinary casts from healthy subjects and patients with glomerulonephritis. Br Med J (Clin Res Ed) 287: 1838–1840.
Faraggiana T, Churg J, Grishman E, et al (1981) Light- and electron-microscopic histochemistry of Fabry’s disease. Am J Pathol 103: 247–262.
Farge D, Nadler S, Wolfe LS, Barre P, Jothy S (1985) Diagnostic value of kidney biopsy in heterozygous Fabry’s disease. Arch Pathol Lab Med 109: 85–88.
Fukuoka S, Kobayashi K (2001) Analysis of the C-terminal structure of urinary Tamm-Horsfall protein reveals that the release of the glycosyl phosphatidylinositol-anchored counterpart from the kidney occurs by phenylalanine-specific proteolysis. Biochem Biophys Res Commun 289: 1044–1048.
Glass RB, Astrin KH, Norton KI, et al (2004) Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. J Comput Assist Tomogr 28: 158–168.
Gresh L, Fischer E, Reimann A, et al (2004) A transcriptional network in polycystic kidney disease. Embo J 23: 1657–1668.
Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R (1978) Early renal changes in hemizygous and heterozygous patients with Fabry’s disease. Kidney Int 13: 223–235.
Hart TC, Gorry MC, Hart PS, et al (2002) Mutations of the UMOD gene are responsible for medullary cystic kidney disease 2 and familial juvenile hyperuricaemic nephropathy. J Med Genet 39: 882–892.
Hodanova K, Majewski J, Kublova M, et al (2005) Mapping of a new candidate locus for uromodulin-associated kidney disease (UAKD) to chromosome 1q41. Kidney Int 68: 1472–1482.
Hoyer JR, Seiler MW (1979) Pathophysiology of Tamm-Horsfall protein. Kidney Int 16: 279–289.
Kreft B, Jabs WJ, Laskay T, et al (2002) Polarized expression of Tamm-Horsfall protein by renal tubular epithelial cells activates human granulocytes. Infect Immun 70: 2650–2656.
Kumar S, Muchmore A (1990) Tamm-Horsfall protein—uromodulin (1950–1990). Kidney Int 37: 1395–1401.
Masson C, Cisse I, Simon V, Insalaco P, Audran M (2004) Fabry disease: a review. Joint Bone Spine 71: 381–383.
McNary WF, Lowenstein LM (1965) A morphological study of the renal lesion in angiokeratoma corporis diffusum universale (Fabry’s disease). J Urol 93: 641–648.
Morel-Maroger L, Ganter P, Ardaillou R, Cathelineau G, Richet G (1966) [Histochemical study of a lipid thesaurismosis with renal, cutaneous and neurologic involvement. Its relation to Fabry’s angiokeratosis and familial renal cytodystrophy]. Bull Mem Soc Med Hop Paris 117: 49–57.
Nakai S, Sugitani Y, Sato H, et al (2003) Crucial roles of Brn1 in distal tubule formation and function in mouse kidney. Development 130: 4751–4759.
Okuda S (2000) Renal involvement in Fabry’s disease. Intern Med 39: 601–602.
Pabico RC, Atancio BC, McKenna BA, Pamukcoglu T, Yodaiken R (1973) Renal pathologic lesions and functional alterations in a man with Fabry’s disease. Am J Med 55: 415–425.
Parchoux B, Guibaud P, Maire I, et al (1978) [Fabry’s disease. Initial nephrogenic diabetes insipidus in children]. Pediatrie 33: 757–765.
Peach RJ, Day WA, Ellingsen PJ, McGiven AR (1988) Ultrastructural localization of Tamm-Horsfall protein in human kidney using immunogold electron microscopy. Histochem J 20: 156–164.
Rampoldi L, Caridi G, Santon D, et al (2003) Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 12: 3369–3384.
Rindler MJ, Naik SS, Li N, Hoops TC, Peraldi MN (1990) Uromodulin (Tamm-Horsfall glycoprotein/uromucoid) is a phosphatidylinositol-linked membrane protein. J Biol Chem 265: 20784–20789.
Scolari F, Caridi G, Rampoldi L, et al (2004) Uromodulin storage diseases: clinical aspects and mechanisms. Am J Kidney Dis 44: 987–999.
Serafini-Cessi F, Malagolini N, Hoops TC, Rindler MJ (1993) Biosynthesis and oligosaccharide processing of human Tamm-Horsfall glycoprotein permanently expressed in HeLa cells. Biochem Biophys Res Commun 194: 784–790.
Schenk EA, Schwartz RH, Lewis RA (1971) Tamm-Horsfall mucoprotein. I. Localization in the kidney. Lab Invest 25: 92–95.
Sikri KL, Foster CL, MacHugh N, Marshall RD (1981) Localization of Tamm-Horsfall glycoprotein in the human kidney using immuno-fluorescence and immuno-electron microscopical techniques. J Anat 132: 597–605.
Tondeur M, Resibois A (1969) Fabry’s disease in children. An electron microscopic study. Virchows Arch B Cell Pathol 2: 239–254.
Vylet’al P, Kublova M, Kalbacova M, et al (2006) Alterations of uromodulin biology: a common denominator of the genetically heterogeneous FJHN/MCKD syndrome. Kidney Int 70: 1155–1169.
Wenk RE, Bhagavan BS, Rudert J (1981) Tamm-Horsfall uromucoprotein and the pathogenesis of casts, reflux nephropathy, and nephritides. Pathobiol Annu 11: 229–257.
Wornell P, Dyack S, Crocker J, Yu W, Acott P (2006) Fabry disease and nephrogenic diabetes insipidus. Pediatr Nephrol 21: 1185–1188.
Yoshida T, Kurella M, Beato F, et al (2002) Monitoring changes in gene expression in renal ischemia-reperfusion in the rat. Kidney Int 61: 1646–1654.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicating editor: Ed Wraith
Competing interests: None declared
References to electronic databases: Fabry disease: OMIM 301500. α-Galactosidase A: EC 3.2.1.22. Uromodulin, OMIM 191845.
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Vylet’al, P., Hůlková, H., Živná, M. et al. Abnormal expression and processing of uromodulin in Fabry disease reflects tubular cell storage alteration and is reversible by enzyme replacement therapy. J Inherit Metab Dis 31, 508–517 (2008). https://doi.org/10.1007/s10545-008-0900-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-008-0900-3